Document:

Fourth Amendment to Amended and Restated Financing Agreement

 EXHIBIT 10.27 
 EXECUTION COPY 
 FOURTH AMENDMENT 
 TO AMENDED AND RESTATED FINANCING AGREEMENT 
 FOURTH AMENDMENT, dated as of
September 6, 2007 (the “Fourth Amendment”), to the Financing Agreement referred to below, by and among (i) ENHERENT CORP., a Delaware corporation (“enherent” or the “Parent”), and each
Subsidiary of Parent listed as a borrower on the signature pages thereto (together with the Parent, each, a “Borrower” and collectively, the “Borrowers”), and (ii) ABLECO FINANCE LLC, a Delaware limited
liability company (“Ableco”) as lender and as agent (in such capacity, the “Agent”) for itself and each Person that purchases any portion of Ableco’s rights and obligations under the Financing Agreement
pursuant to Sections 2.07 and 10.07 thereof (collectively with Ableco, the “Lenders”). 
 WHEREAS, the Borrowers, the Agent
and the Lenders are parties to the Amended and Restated Financing Agreement dated as of April 1, 2005 (as amended to date, the “Financing Agreement”), pursuant to which the Lenders have agreed to make certain term loans and
revolving loans to the Borrowers from time to time in an aggregate principal amount at any time outstanding not to exceed the aggregate amount set forth in the Financing Agreement; and 
 WHEREAS, the Borrowers have requested that the Agent and the Lenders amend certain provisions of the Financing Agreement to provide for, among other
things, (a) the decrease in the Revolving Credit Commitment from $6,000,000 to $4,500,000 at any time outstanding and (b) the extension of the Revolving Loan Maturity Date from April 1, 2008 to April 1, 2009, all in accordance
with and subject to the terms and conditions set forth herein; 
 NOW THEREFORE, in consideration of the premises and other good and valuable
consideration, the parties hereto hereby agree as follows: 
 1.1 Definitions in Fourth Amendment. Any capitalized term used herein and
not defined shall have the meaning assigned to it in the Financing Agreement. 
 1.2 Amendment to the Financing Agreement. 

(a) Section 1.01 of the Financing Agreement is hereby amended by adding the following new definitions in their appropriate
alphabetical order, as follows: 
 ““Fourth Amendment” means the Fourth Amendment to Amended and
Restated Financing Agreement, dated as of September 6, 2007, by and among the Borrowers, the Agent and the Lenders.” 
 ““Fourth Amendment Effective Date” means the later of (i) September 6, 2007 and (ii) the date on which all of the conditions precedent set forth in Section 2 of the Fourth Amendment have been
satisfied or waived in writing.” 

 (b) Section 1.01 of the Financing Agreement is hereby amended by amending and
restating each of the definitions listed below in their entirety to read as follows: 
 “Revolving Credit
Commitment” means the commitment of the Lender to make Revolving Loans to the Borrowers in an aggregate principal amount at any time outstanding not to exceed $4,500,000.00, as such amount may be terminated, reduced or increased from time
to time in accordance with the terms of this Agreement.” 
 ““Revolving Loan Maturity Date” means
April 1, 2009 or such earlier date on which the Revolving Loans shall become due and payable, in whole or in part, in accordance with the terms of this Agreement and the other Loan Documents.” 
 2. Conditions to Effectiveness. This Fourth Amendment shall become effective only upon satisfaction in full, in a manner satisfactory to the
Agent, of the following conditions precedent (the first date upon which all such conditions shall have been satisfied being herein called the “Fourth Amendment Effective Date”): 
 (a) The representations and warranties contained herein, in Section 5.01 of the Financing Agreement and in each other Loan Document
and certificate or other writing delivered to the Agent pursuant hereto on or prior to the Fourth Amendment Effective Date shall be correct on and as of the Fourth Amendment Effective Date as though made on and as of such date, except to the extent
that such representations and warranties (or any schedules related thereto) expressly relate solely to an earlier date (in which case such representations and warranties shall be true and correct on and as of such date); and, no Default or Event of
Default shall have occurred and be continuing on the Fourth Amendment Effective Date. 
 (b) The Agent shall have received
counterparts of this Fourth Amendment which bear the signatures of each Borrower. 
 (c) The Borrowers shall have paid to the
Agent a nonrefundable amendment fee in an amount equal to $60,000 (the “Amendment Fee”), which Amendment Fee shall be (i) payable on or before the Fourth Amendment Effective Date, (ii) fully-earned when paid and
(iii) in addition to any fees payable to the Agent or the Lenders pursuant to the Financing Agreement or any amendment thereof. Each Borrower hereby authorizes the Agent to, and the Agent may, charge the Loan Account pursuant to
Section 3.01 of the Financing Agreement with the amount of the Amendment Fee due hereunder. 
 (d) All legal matters
incident to this Fourth Amendment shall be satisfactory to the Agent and its counsel. 
  

 -2- 

 3. Representations and Warranties. Each Loan Party hereby represents and warrants to the Agent and
the Lenders as follows: 
 (a) Representations and Warranties; No Event of Default. The representations and warranties
herein, in Section 5.01 of the Financing Agreement and in each other Loan Document and certificate or other writing delivered to the Agent or the Lenders pursuant hereto on or prior to the Fourth Amendment Effective Date shall be correct on and
as of the Fourth Amendment Effective Date as though made on and as of such date, except to the extent that such representations and warranties (or any schedules related thereto) expressly relate solely to an earlier date (in which case such
representations and warranties shall be true and correct on and as of such date); and no Default or Event of Default shall have occurred and be continuing on the Fourth Amendment Effective Date. 
 (b) Organization, Good Standing, Etc. Such Loan Party (i) is a corporation duly organized, validly existing and in good
standing under the laws of the state of its organization, (ii) has all requisite power and authority to execute, deliver and perform this Fourth Amendment and to perform the Financing Agreement, as amended hereby, and (iii) is duly
qualified to do business and is in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification necessary. 
 (c) Authorization, Etc. The execution, delivery and performance by such Loan Party of this Fourth Amendment, and the performance by
such Loan Party of the Financing Agreement, as amended hereby, (i) have been duly authorized by all necessary action, (ii) do not and will not contravene such Loan Party’s charter or by-laws, any applicable law or any contractual
restriction binding on or otherwise affecting it or any of its properties, (iii) do not and will not result in or require the creation of any Lien (other than pursuant to any Loan Document) upon or with respect to any of its properties, and
(iv) do not and will not result in any suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization or approval applicable to its operations or any of its properties. 
 (d) Governmental Approvals. No authorization or approval or other action by, and no notice to or filing with, any Governmental
Authority or other regulatory body is required in connection with the due execution, delivery and performance by such Loan Party of this Fourth Amendment, or for the performance of the Financing Agreement, as amended hereby. 
 (e) Enforceability of Loan Documents. Each of this Fourth Amendment, the Financing Agreement, as amended hereby, and each other
Loan Document to which such Loan Party is a party is a legal, valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its terms, except as such enforceability may be limited by or subject to any
bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally. 
 4. Continued
Effectiveness of Financing Agreement. Each Borrower hereby (i) confirms and agrees that each Loan Document to which it is a party is, and shall continue to 

  

 -3- 

 
be, in full force and effect and is hereby ratified and confirmed in all respects except that on and after the Fourth Amendment Effective Date all references
in any such Loan Document to “the Financing Agreement”, “thereto”, “thereof”, “thereunder” or words of like import referring to the Financing Agreement shall mean the Financing Agreement as amended by this
Fourth Amendment, and (ii) confirms and agrees that to the extent that any such Loan Document purports to assign or pledge to the Agent or any Lender, or to grant to the Agent or any Lender a Lien on any collateral as security for the
Obligations of such Borrower from time to time existing in respect of the Financing Agreement and the other Loan Documents, such pledge, assignment and/or grant of a Lien is hereby ratified and confirmed in all respects. 
 5. Miscellaneous. 
 (a) This Fourth Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the
same agreement. 
 (b) Section and paragraph headings herein are included for convenience of reference only and shall not
constitute a part of this Fourth Amendment for any other purpose. 
 (c) This Fourth Amendment shall be governed by, and
construed in accordance with, the laws of the State of New York. 
 (d) Each Borrower hereby acknowledges and agrees that this
Fourth Amendment constitutes a “Loan Document” under the Financing Agreement. Accordingly, it shall be an Event of Default under the Financing Agreement if (i) any representation or warranty made by a Borrower under or in connection
with this Fourth Amendment shall have been untrue, false or misleading in any material respect when made, or (ii) a Borrower shall fail to perform or observe any term, covenant or agreement contained in this Fourth Amendment. 
 (e) The Borrowers will pay on demand all reasonable out-of-pocket costs and expenses of the Agent and the Lenders in connection with the
preparation, execution and delivery of this Fourth Amendment, including, without limitation, the reasonable fees, disbursements and other charges of Schulte Roth & Zabel LLP, counsel to the Agent and the Lenders. 
  

 -4- 

 IN WITNESS WHEREOF, the parties hereto have caused this Fourth Amendment to be executed and delivered as
of the date first above written. 
  

			
	BORROWERS:
	
	ENHERENT CORP.
		
	By:	 	 /s/ Pamela Fredette

	Name:	 	Pamela Fredette
	Title:	 	Chief Executive Officer
	
	AGENT and LENDER:
	
	 ABLECO FINANCE LLC, as lender and agent, on behalf of itself and its affiliate assigns

		
	By:	 	 /s/ Daniel E. Wolf

	Name:	 	Daniel E. Wolf
	Title:	 	President

  

 -5-Consulting Agreement by and between the Company and Donald R. Kiepert, Jr.

 Exhibit 10.01 
 CONSULTING AGREEMENT 
 THIS CONSULTING
AGREEMENT (the “Agreement”) is made and entered into as of this 26th day of July, 2007 (the “Effective Date”) by and between Point
Therapeutics, Inc., a Delaware corporation (the “Company”), and Donald R. Kiepert, Jr. (the “Consultant”). 
 The
Company wishes to engage the Consultant to provide assistance and expertise for the Company and otherwise to render consulting services upon the terms and conditions contained in this Agreement. 
 NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, accepted and agreed to, the Company and the Consultant hereby agree as follows: 
 1. TERM; SERVICES. 
 1.1 Commencing as of the Effective Date and continuing until terminated by either party hereto upon thirty (30) days written notice
to the other party (the “Term”), the Consultant agrees that he will provide certain consulting services to the Company as from time to time requested by the Company (the “Services”). 
 1.2 The Consultant represents and warrants to the Company that he is under no contractual or other restriction or obligation which is
inconsistent with the execution of this Agreement, or which will materially interfere with the performance of his duties hereunder. 
 2.
CONSULTING FEE. 
 2.1 The Company shall pay the Consultant a consulting fee of Two Hundred Fifty Dollars ($250.00) per
hour to be billed to the Company by the Consultant in quarter hour increments not to exceed an aggregate of Two Thousand Dollars ($2,000.00) per day for services performed during the Term (the “Consulting Fee”). The Consultant shall be
compensated promptly upon the Company’s receipt of a weekly or bi-weekly time sheet in the form attached hereto as Exhibit A. 
 2.2 The Consultant shall be entitled to prompt reimbursement for all pre-approved travel and other out-of-pocket expenses incurred in the performance of his duties hereunder, upon submission and approval of written
statements and bills. 
 2.3 The Consultant agrees that all services hereunder will be rendered by him as an independent
contractor and that this Agreement does not create an employer-employee relationship between the Consultant and the Company. The Consultant shall have no right to receive any employee benefits, including, but not limited to, health and accident
insurance, life insurance, sick leave and/or vacation. 
 3. PROPRIETARY RIGHTS. 
 3.1 Trade Secrets. The Consultant acknowledges and agrees that rendering of Services to the Company will necessarily involve
understanding of and access to “trade secrets” of the Company as hereinafter defined, and “confidential and proprietary information” of the Company. The Consultant agrees during the Term of this Agreement and for a period of five
(5) years thereafter, not to disclose to any unauthorized third party or use for the Consultant’s own benefit any of the trade secret or confidential or proprietary information belonging to the Company. For the purposes hereof, “trade
secret” is information not generally known to the trade, which gives the Company an advantage over its competitors. Trade secrets include without limitation, research being planned and developed, research methods and processes, materials used
in research, inventions, information concerning the filing or pendency of patent applications and the Company’s business and legal plans, finances, competitive position, customers and vendors. 
 3.2 Concepts and Ideas. Those concepts and ideas disclosed by the Company to the Consultant or which are first developed by the
Consultant during the course of performance of Services hereunder and which relate to the Company’s present, past or prospective activities, services and products, all of which shall remain the sole and exclusive property of the Company. The
Consultant shall have no publication rights and all of the same shall belong exclusively to the Company. 

 3.3 Confidential Information. That secret or proprietary information of whatever
kind or nature disclosed to the Consultant (whether or not invented, discovered or developed by the Consultant) or first developed by the Consultant in the course of performance of Services hereunder. Such secret or proprietary information shall
include (unless such information is generally available to the public or known in the industry through no action of the Consultant) information relating to the design, manufacture, application, know-how, research and development relating to the
Company’s products, materials, operating and other cost data, price lists and data relating to pricing of the Company’s products. Such secret or proprietary information shall specifically include, without limitation, all secret or
proprietary information contained in the Company’s manuals, memoranda, plans, drawings and designs, specifications, supply sources, customer lists and records legended or otherwise identified by the Company or the Board of Directors (the
“Board”) as Confidential Information. 
 3.4 Non-Confidential Information. The Consultant’s obligations
under this Section 3 do not apply to any confidential and proprietary material which (a) is or becomes publicly known under circumstances involving no breach by the Consultant of the terms; and/or (b) is generally disclosed to third
parties; and/or (c) was generally known by the Consultant prior to receipt of confidential or proprietary material by the Consultant; and/or (d) was or is approved for release by written authorization of an authorized representative of the
Company. 
 3.5 Non-Disclosure to Third Parties. Except as required by the Consultant’s duties, the Consultant
shall not, at any time, directly or indirectly, use, publish, disseminate or otherwise disclose any Confidential Information, Concepts or Ideas relating to the present, past or prospective business of the Company to any third party without the prior
written consent of the Company, which consent may be denied in each instance and all of the same, together with publication rights, shall belong exclusively to the Company; provided, however, that if the Consultant is required by law (by oral
questions, interrogatories, requests for information or documents, subpoena, civil investigative demand, legal process or similar process), or receives notice that action may be taken to require the Consultant, under law, to disclose any
Confidential Information, it is agreed that, to the extent not legally prohibited, the Consultant will provide to the Company prompt notice of such request so that it may seek an appropriate protective order and/or waive compliance with the
provisions of this Agreement. The Consultant may disclose without liability hereunder only that portion of the Confidential Information that the Consultant is advised by counsel is legally required to be disclosed; provided, that to the
extent not legally prohibited, the Consultant shall give the Company written notice of the information to be disclosed as far in advance of the Consultant’s disclosure as is practicable and, upon the Company’s written request, use
commercially reasonable efforts to assist the Company in its efforts to obtain assurances that confidential treatment will be accorded to such information. 
 3.6 Documents, etc. All documents, procedural manuals, guides, specifications, plans, drawings, designs and similar materials, lists of present, past or prospective customers, customer proposals, invitations to
submit proposals, price lists and data relating to the pricing of the Company’s products and services, records, notebooks and similar repositories of or containing Confidential Information (including all copies thereof) that come into the
Consultant’s possession or control by reason of the Consultant’s relationship, whether prepared by the Consultant or others: (a) are the property of the Company, (b) will not be used by the Consultant in any way adverse to the
Company, (c) will not be removed from the Company’s premises (except as the Consultant’s duties require) and (d) at the termination (for whatever reason), of the Consultant’s relationship with the Company, will be left with,
or forthwith returned by the Consultant to, the Company. 
 3.7 Patents, etc. Any interest in patents, patent
applications, inventions, technological innovations, copyrights, copyrightable works, developments, discoveries, designs, processes, formulas, know-how, data and analysis, whether patentable or not (“Inventions”), which the Consultant, as
a result of rendering consulting Services to the Company under this Agreement, may conceive or develop shall belong exclusively to the Company. 
 4. EQUITABLE RELIEF. The Consultant agrees that any breach of Section 3 above by him would cause irreparable damage to the Company and that, in the event of such breach, the Company shall have, in addition to any and all
remedies of law, the right to an injunction, specific performance or other equitable relief to prevent the violation or threatened violation of the Consultant’s obligations hereunder. In addition, the Company agrees to indemnify the Consultant
and hold him harmless in the event of any legal action resulting from his work performance on behalf of the Company, unless such action results from his own gross negligence or willful misconduct. 
 5. WAIVER. Any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent
breach of the same or any other provision hereof. All waivers by the Company shall be in writing. 

 6. SEVERABILITY; REFORMATION. In case any one or more of the provisions or parts of a provision
contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Agreement; and
this Agreement shall, to the fullest extent lawful, be reformed and construed as if such invalid or illegal or unenforceable provision, or part of a provision, had never been contained herein, and such provision or part reformed so that it would be
valid, legal and enforceable to the maximum extent possible. Without limiting the generality of the foregoing, if any provision (or part of any provision) contained in this Agreement shall for any reason be held to be excessively broad as to
duration, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the fullest extent compatible with then existing applicable law. 
 7. ASSIGNMENT. The Company shall have the right to assign its rights and obligations under this Agreement to a party which assumes the
Company’s obligations hereunder and in such event, the Company shall give notice to the Consultant of such intention and the Assignment will only be effective if the Consultant assents to the Assignment. If the Consultant does not assent to the
Assignment, he will so notify the Company (in accordance with Article 10), and thereafter this Agreement shall be null and void and without further force or effect. The Consultant shall not have the right to assign his duties or obligations under
this Agreement without the prior written consent of the Company. This Agreement shall be binding upon and inure to the benefit of the Consultant’s heirs and legal representatives in the event of his death or disability. 
 8. HEADINGS. Headings and sub-headings are for convenience only and shall not be deemed to be a part of this Agreement. 
 9. AMENDMENTS. This Agreement may be amended or modified, in whole or in part, only by an instrument in writing signed by all parties hereto.

 10. NOTICES. Any notices or other communications required hereunder shall be in writing and shall be deemed given when delivered in
person, sent by facsimile or by email, or when mailed, by certified or registered first-class mail, postage prepaid, return receipt requested, addressed, if to the Company, at 70 Walnut Street, Wellesley Hills, MA 02481, Facsimile: 781-239-8005,
Attn: Chief Restructuring Officer, or to the Consultant at the address appearing below his signature or such other address of which a party shall have notified the other in accordance with the provisions of this Section 10. 
 11. COUNTERPARTS. This Agreement may be executed in two or more counterparts, each of which shall constitute an original and all of which shall be
deemed a single agreement. 
 12. GOVERNING LAW. This Agreement shall be construed in accordance with and governed for all purposes by
the laws (other than the conflicts of laws rules) of The Commonwealth of Massachusetts. 
 13. SURVIVAL. The provisions of this
Agreement shall survive the termination of the Consultant’s relationship with the Company in accordance with their terms. 
 14. OTHER
AGREEMENTS. This Agreement supersedes all prior understandings and agreements between the Consultant and the Company, whether oral or written, with respect to the subject matter hereof. 
 EXECUTED as an instrument under seal as of the date first above written. 
  

			
	POINT THERAPEUTICS, INC.
		
	By:	 	 /s/ Michael P. Duffy

		 	Michael P. Duffy
		 	Chief Restructuring Officer
	
	CONSULTANT
		
	By:	 	 /s/ Donald R. Kiepert, Jr.

		 	Donald R. Kiepert, Jr.
		 	 Address: 236 Commonwealth Ave., Apt. 2
   Boston, MA 02116

 Exhibit A 
 Time Sheet 
 Consultant: Donald R. Kiepert, Jr. 
  

					
	Date	  	 Description
	  	 # of Hours

		  		  	
		  		  	
		  		  	
		  		  	

  

	
	Please submit Time Sheet to:
	
	Michael P. Duffy
	Chief Restructuring Officer
	Point Therapeutics, Inc.
	 70 Walnut Street
 Wellesley Hills, MA 02481
 mduffy@pther.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]